Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Metabolic and cardiovascular adaptations to an 8-wk lifestyle weight loss intervention in younger and older obese men

J. Vion, V. Sramkova, E. Montastier, MA. Marquès, S. Caspar-Bauguil, T. Duparc, LO. Martinez, V. Bourlier, I. Harant, D. Larrouy, N. Moussaoui, S. Bonnel, C. Vindis, C. Dray, P. Valet, JS. Saulnier-Blache, JP. Schanstra, C. Thalamas, N. Viguerie,...

. 2021 ; 321 (3) : E325-E337. [pub] 20210712

Language English Country United States

Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't

The number of older obese adults is increasing worldwide. Whether obese adults show similar health benefits in response to lifestyle interventions at different ages is unknown. The study enrolled 25 obese men (body mass index: 31-39 kg/m2) in two arms according to age (30-40 and 60-70 yr old). Participants underwent an 8-wk intervention with moderate calorie restriction (∼20% below individual energy requirements) and supervised endurance training resulting in ∼5% weight loss. Body composition was measured using dual energy X-ray absorptiometry. Insulin sensitivity was assessed during a hypersinsulinemic-euglycemic clamp. Cardiometabolic profile was derived from blood parameters. Subcutaneous fat and vastus lateralis muscle biopsies were used for ex vivo analyses. Two-way repeated-measure ANOVA and linear mixed models were used to evaluate the response to lifestyle intervention and comparison between the two groups. Fat mass was decreased and bone mass was preserved in the two groups after intervention. Muscle mass decreased significantly in older obese men. Cardiovascular risk (Framingham risk score, plasma triglyceride, and cholesterol) and insulin sensitivity were greatly improved to a similar extent in the two age groups after intervention. Changes in adipose tissue and skeletal muscle transcriptomes were marginal. Analysis of the differential response to the lifestyle intervention showed tenuous differences between age groups. These data suggest that lifestyle intervention combining calorie restriction and exercise shows similar beneficial effects on cardiometabolic risk and insulin sensitivity in younger and older obese men. However, attention must be paid to potential loss of muscle mass in response to weight loss in older obese men.NEW & NOTEWORTHY Rise in obesity and aging worldwide are major trends of critical importance in public health. This study addresses a current challenge in obesity management. Do older obese adults respond differently to a lifestyle intervention composed of moderate calorie restriction and supervised physical activity than younger ones? The main conclusion of the study is that older and younger obese men similarly benefit from the intervention in terms of cardiometabolic risk.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024980
003      
CZ-PrNML
005      
20211026134232.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1152/ajpendo.00109.2021 $2 doi
035    __
$a (PubMed)34250814
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vion, Julie $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
245    10
$a Metabolic and cardiovascular adaptations to an 8-wk lifestyle weight loss intervention in younger and older obese men / $c J. Vion, V. Sramkova, E. Montastier, MA. Marquès, S. Caspar-Bauguil, T. Duparc, LO. Martinez, V. Bourlier, I. Harant, D. Larrouy, N. Moussaoui, S. Bonnel, C. Vindis, C. Dray, P. Valet, JS. Saulnier-Blache, JP. Schanstra, C. Thalamas, N. Viguerie, C. Moro, D. Langin
520    9_
$a The number of older obese adults is increasing worldwide. Whether obese adults show similar health benefits in response to lifestyle interventions at different ages is unknown. The study enrolled 25 obese men (body mass index: 31-39 kg/m2) in two arms according to age (30-40 and 60-70 yr old). Participants underwent an 8-wk intervention with moderate calorie restriction (∼20% below individual energy requirements) and supervised endurance training resulting in ∼5% weight loss. Body composition was measured using dual energy X-ray absorptiometry. Insulin sensitivity was assessed during a hypersinsulinemic-euglycemic clamp. Cardiometabolic profile was derived from blood parameters. Subcutaneous fat and vastus lateralis muscle biopsies were used for ex vivo analyses. Two-way repeated-measure ANOVA and linear mixed models were used to evaluate the response to lifestyle intervention and comparison between the two groups. Fat mass was decreased and bone mass was preserved in the two groups after intervention. Muscle mass decreased significantly in older obese men. Cardiovascular risk (Framingham risk score, plasma triglyceride, and cholesterol) and insulin sensitivity were greatly improved to a similar extent in the two age groups after intervention. Changes in adipose tissue and skeletal muscle transcriptomes were marginal. Analysis of the differential response to the lifestyle intervention showed tenuous differences between age groups. These data suggest that lifestyle intervention combining calorie restriction and exercise shows similar beneficial effects on cardiometabolic risk and insulin sensitivity in younger and older obese men. However, attention must be paid to potential loss of muscle mass in response to weight loss in older obese men.NEW & NOTEWORTHY Rise in obesity and aging worldwide are major trends of critical importance in public health. This study addresses a current challenge in obesity management. Do older obese adults respond differently to a lifestyle intervention composed of moderate calorie restriction and supervised physical activity than younger ones? The main conclusion of the study is that older and younger obese men similarly benefit from the intervention in terms of cardiometabolic risk.
650    12
$a fyziologická adaptace $7 D000222
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a složení těla $7 D001823
650    _2
$a kardiovaskulární systém $x metabolismus $7 D002319
650    _2
$a lidé $7 D006801
650    12
$a životní styl $7 D008019
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a obezita $x metabolismus $7 D009765
650    12
$a programy na snížení hmotnosti $7 D061217
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sramkova, Veronika $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Department of Pathophysiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic $u Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Prague, Czech Republic, Paul Sabatier University, Toulouse, France
700    1_
$a Montastier, Emilie $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Prague, Czech Republic, Paul Sabatier University, Toulouse, France $u Departments of Nutrition and Clinical Biochemistry, Toulouse University Hospitals, Toulouse, France
700    1_
$a Marquès, Marie-Adeline $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Prague, Czech Republic, Paul Sabatier University, Toulouse, France
700    1_
$a Caspar-Bauguil, Sylvie $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Prague, Czech Republic, Paul Sabatier University, Toulouse, France $u Departments of Nutrition and Clinical Biochemistry, Toulouse University Hospitals, Toulouse, France
700    1_
$a Duparc, Thibaut $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Martinez, Laurent O $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Bourlier, Virginie $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Harant, Isabelle $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Larrouy, Dominique $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Moussaoui, Nabila $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Bonnel, Sophie $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Vindis, Cécile $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Clinical Investigation Center, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Toulouse University Hospitals, CIC1436, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Dray, Cédric $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Valet, Philippe $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Saulnier-Blache, Jean-Sébastien $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Schanstra, Joost P $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Thalamas, Claire $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Clinical Investigation Center, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Toulouse University Hospitals, CIC1436, F-CRIN/FORCE Network, Toulouse, France
700    1_
$a Viguerie, Nathalie $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Departments of Nutrition and Clinical Biochemistry, Toulouse University Hospitals, Toulouse, France
700    1_
$a Moro, Cedric $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Prague, Czech Republic, Paul Sabatier University, Toulouse, France
700    1_
$a Langin, Dominique $u Institute of Metabolic and Cardiovascular Diseases, I2MC Team MetaDiab, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, UMR 1297, F-CRIN/FORCE Network, Toulouse, France $u Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Prague, Czech Republic, Paul Sabatier University, Toulouse, France $u Departments of Nutrition and Clinical Biochemistry, Toulouse University Hospitals, Toulouse, France $u Institut Universitaire de France, IUF, Paris, France
773    0_
$w MED00000286 $t American journal of physiology. Endocrinology and metabolism $x 1522-1555 $g Roč. 321, č. 3 (2021), s. E325-E337
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34250814 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134238 $b ABA008
999    __
$a ok $b bmc $g 1714151 $s 1145487
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 321 $c 3 $d E325-E337 $e 20210712 $i 1522-1555 $m American journal of physiology: endocrinology and metabolism $n Am J Physiol Endocrinol Metab $x MED00000286
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...